Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication January 20, 2021
- Accepted for publication May 13, 2021
- Published online October 1, 2021.
Article Versions
- previous version (May 20, 2021 - 12:13).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Jeremie Calais1–4,
- Andrei Gafita1,
- Matthias Eiber1,5,
- Wesley R. Armstrong1,
- Jeannine Gartmann1,
- Pan Thin1,
- Kathleen Nguyen1,
- Vincent Lok1,
- Laura Gosa1,
- Tristan Grogan6,
- Rouzbeh Esfandiari7,
- Martin Allen-Auerbach1,3,4,
- Andrew Quon1,3,4,
- Shadfar Bahri1,3,4,
- Pawan Gupta1,
- Linda Gardner1,
- David Ranganathan8,
- Roger Slavik1,
- Magnus Dahlbom1,2,
- Ken Herrmann1,9,
- Ebrahim Delpassand7,8,
- Wolfgang P. Fendler1,9 and
- Johannes Czernin1,3,4
- 1Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California;
- 2Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;
- 3Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California;
- 4Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California;
- 5Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany;
- 6Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California;
- 7Excel Diagnostics and Nuclear Oncology Center, Houston, Texas;
- 8RadioMedix, Inc., Houston, Texas; and
- 9Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
- For correspondence or reprints, contact Jeremie Calais (jcalais{at}mednet.ucla.edu).
Statistics from Altmetric.com
Cited By...
Article usage
In this issue
Jump to section
Related Articles
Cited By...
- Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy
- SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
- Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
- Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer
- From Concept to Regulatory Drug Approval: Lessons for Theranostics
- SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer--Use of Imaging Agents in Therapeutic Drug Development and Approval
- Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study
- The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
- Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice